Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1058-1062

  Huang, Tsi Shu ^a   Kunin, Calvin M ^b   Lee, Susan Shin Jung ^a,c   Chen, Yao Shen ^a   Tu, Hui Zin ^a   Liu, Yung Ching ^a,c  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Fluoroquinolone resistance; TB; Treatment

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; GENE MUTATION; GENERAL HOSPITAL; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TAIWAN;

AMINO ACID SUBSTITUTION; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HOSPITALS, VETERANS; HUMANS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; TAIWAN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 29444440874     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki353     Document Type: Article

References (40)

1. Gillespie SH, Kennedy N. Fluoroquinolones; a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2: 265-71.
2. Infectious Diseases Society of the Republic of China; Society of Tuberculosis, Taiwan; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; C Y Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines. Guidelines for chemotherapy of tuberculosis in Taiwan. J Microbiol Immunol Infect 2004; 37: 382-4.
3. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
4. Baohong J, Lounis N, Maslo C et al. In vitro and in vivo activites of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-9.
5. Berlin OGW, Young LS, Bruckner DA. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987; 19: 611-5.
6. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44: 393-5.
7. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40: 885-8.
8. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213-21.
9. Garcia-Rodriguez JA, Garcia ACG. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32: 797-808.
10. Grassi C. New drugs for tuberculosis. Exp Opin Investig Drugs 1997; 6: 1211-26.
11. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1341-4.
12. Klemens SP, Sharpe CA, Rogge MC et al. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38: 476-9.
13. Yew WW, Au KF, Lee J et al. Levofloxacin in treatment of drug-resistant tuberculosis. Intect J Tuberc Lung Dis 1997; 1: 89.
14. Alangaden GJ, Manavathu EK, Vakulenko SB et al. Characterization of fluoroquinolone-resistant mutant isolates of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-3.
15. Cambau E, Sougakoff W, Besson M et al. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479-83.
16. Takiff HE, Salazaar L, Guerrero C et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-80.
17. Williams KJ, Piddock LJV. gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong. J Antimicrob Chemother 1996; 37: 1032-4.
18. Kocagoz T, Hackbarth CJ, Unsal I et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-74.
19. Cardinale E, Dromigny JA, Tall F et al. Fluoroquinolone susceptibility of Campylobacter isolates, Senegal. Emerging Infect Dis 2003; 9: 1479-81.
20. Chen FJ, Lauderdale TL, McDonald LC et al. Molecular epidemiology of emerging reduced susceptibility to fluoroquinolones in Escherichia coli. J Med Microbiol 2004; 53: 85-6.
21. Chen JY, Siu LK, Chen YH et al. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. Microb Drug Resist 2001; 7:47-53.
22. Chen JY, Fung CP, Wang CC et al. In vitro susceptibility of six fluoroquinolones against invasive Streptococcus pneumoniae isolated from 1996 to 2001 in Taiwan. Microb Drug Resist 2003; 9: 211-7.
23. Hamer DH, Gill CJ. From the farm to the kitchen table: The negative impact of antimicrobial use in animals on humans. Nutr Rev 2002; 60: 261-4.
24. Hsueh PR. Ciprofloxacin-resistant Salmonella enterica Typhimurium and Choleraesuis from pigs to humans, Taiwan. Emerging Infect Dis 2004; 10: 60-8.
25. Hsueh PR, Chen ML, Sun CC et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a University Hospital in Taiwan, 1981-1999. Emerging Infect Dis 2002; 8: 132-7.
26. Kent PT, Kubica GP. Public Health Mycobacteriology: A Guide for The Level III Laboratory. Centers for Disease Control, Atlanta, GA, USA, 1985.
27. Chen CC, Shih JF, Lindholm-Levy PJ et al. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis 1989; 140: 987-9.
28. Heifets LB. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In: Heifets LB, ed. Drug Susceptibility In the Chemotherapy of Mycobacterial Infections. Boca Raton: CRC Press, 1991; 89-122.
29. Siddiqi N, Shamim M, Hussain S et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 2002; 46: 443-50.
30. Bozeman L, Burman W, Metchock B et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386-91.
31. Neter J, William Wasserman W, Whitmore GG. Applied Statistics. Boston: Allyn and Bacon, Inc., 1998.
32. Ruiz-Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis. susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
33. Yew W, Piddock L, Li M et al. In vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34: 343-51.
34. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv isolate in human macrophages. Curr Microbiol 1996; 33: 167-75.
35. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 20: 66S-77S.
36. Sreevatsan S, Pan X, Stockbauer KE et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination. Proc Natl Acad Sci USA 1997; 94: 9869-74.
37. Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol 1996; 178: 3791-5.
38. Chang AFB, Yew WW, Chan EWC et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
39. Yew WW, Chan E, Chan CY et al. Genotypic and phenotypic resistance of Mycobacterium tuberculosis to rifamycins and fluoroquinolones. Int J Tuberc Lung Dis 2002; 6: 936-8.
40. Giannoni F, Iona E, Sementilli F et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 2928-33.